Risk stratification of hemodynamically significant patent ductus arteriosus by clinical and genetic factors

• Published in: World journal of pediatrics : WJP Vol. 19; no. 12; pp. 1192 - 1202
• Main Authors: Chen, Yu-Xi, Xiao, Tian-Tian, Chen, Hui-Yao, Chen, Xiang, Wang, Ya-Qiong, Ni, Qi, Wu, Bing-Bing, Wang, Hui-Jun, Lu, Yu-Lan, Hu, Li-Yuan, Cao, Yun, Cheng, Guo-Qiang, Wang, Lai-Shuan, Xiao, Fei-Fan, Yang, Lin, Dong, Xin-Ran, Zhou, Wen-Hao
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.12.2023; Center for Molecular Medicine of Children's Hospital of Fudan University,Institutes of Biomedical Sciences,Fudan University,138 Yi Xue Yuan Road,Shanghai,China%Department of Neonatology,Children's Hospital of Fudan University,National Children's Medical Center,Shanghai,China%Center for Molecular Medicine,Children's Hospital of Fudan University,399 Wanyuan Road,Shanghai 201102,China%Center for Molecular Medicine of Children's Hospital of Fudan University,Institutes of Biomedical Sciences,Fudan University,138 Yi Xue Yuan Road,Shanghai,China; Department of Neonatology,Children's Hospital of Fudan University,National Children's Medical Center,Shanghai,China
• Subjects: Critical Care Medicine; Imaging; Intensive; Maternal and Child Health; Medicine; Medicine & Public Health; Original Article; Pediatric Surgery; Pediatrics; Radiology; Surgery; Neonates; Hemodynamically significant patent ductus arteriosus; Exome sequencing; Multivariate logistic regression; Risk stratification
• ISSN: 1708-8569; 1867-0687
• DOI: 10.1007/s12519-023-00733-7

Background Hemodynamically significant patent ductus arteriosus (hsPDA) is associated with increased comorbidities in neonates. Early evaluation of hsPDA risk is critical to implement individualized intervention. The aim of the study was to provide a powerful reference for the early identification of high-risk hsPDA population and early treatment decisions. Methods We enrolled infants who were diagnosed with PDA and performed exome sequencing. The collapsing analyses were used to find the risk gene set (RGS) of hsPDA for model construction. The credibility of RGS was proven by RNA sequencing. Multivariate logistic regression was performed to establish models combining clinical and genetic features. The models were evaluated by area under the receiver operating curve (AUC) and decision curve analysis (DCA). Results In this retrospective cohort study of 2199 PDA patients, 549 (25.0%) infants were diagnosed with hsPDA. The model [all clinical characteristics selected by least absolute shrinkage and selection operator regression (all CCs)] based on six clinical variables was acquired within three days of life, including gestational age (GA), respiratory distress syndrome (RDS), the lowest platelet count, invasive mechanical ventilation, and positive inotropic and vasoactive drugs. It has an AUC of 0.790 [95% confidence interval (CI) = 0.749–0.832], while the simplified model (basic clinical characteristic model) including GA and RDS has an AUC of 0.753 (95% CI = 0.706–0.799). There was a certain consistency between RGS and differentially expressed genes of the ductus arteriosus in mice. The AUC of the models was improved by RGS, and the improvement was significant (all CCs vs. all CCs + RGS: 0.790 vs. 0.817, P  < 0.001). DCA demonstrated that all models were clinically useful. Conclusions Models based on clinical factors were developed to accurately stratify the risk of hsPDA in the first three days of life. Genetic features might further improve the model performance. 7r3S4-EhCfGZT2hWwKNp8L Video Abstract (MP4 86834 kb)